(Bloomberg) -- UnitedHealth Group Inc.’s Oxford unit, which runshealth plans in the northeastern U.S., will favor Sanofi and Regeneron Pharmaceuticals Inc.’s newcholesterol-cutting shot over a similar treatment madeby Amgen Inc.

Oxford covers about 1.2 million people, according to datacompiled by Bloomberg.

Its patients will have to take Sanofi and Regeneron’s injectionPraluent for 12 weeks without sufficient effect or have a historyof not being able to tolerate the drug before the insurer willcover Amgen’s drug Repatha, the company said in an update postedonline. The policy takes effect on Jan. 1.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Cost-Containment